Lantheus Holdings, Inc. (LNTH) · Oct 22, 2026 · Acquisition
FTC Second Request — HSR waiting period extends until 30 days after substantial compliance
Lantheus’ merger with Curium now faces an FTC Second Request, extending regulatory review and adding uncertainty to the planned first-half 2027 close.
Lantheus is a radiopharmaceutical company pursuing a combination with Curium that would pair Lantheus’ U.S. diagnostic business with Curium’s broader manufacturing and therapeutic platform. The merger has moved from routine clearance into deeper antitrust review. The FTC’s Second Request requires both parties to provide additional information and documents, rather than allowing the initial waiting period to expire. 〔0〕
This is a delay and execution risk, not a deal termination. The filing says the HSR waiting period now runs until 30 days after both sides substantially comply, unless the FTC ends it sooner. 〔1〕 That makes the previously stated first-half 2027 closing target less certain, while leaving the transaction formally intact.
The headline timing has not changed, but the path to closing is now more demanding. Management continues to expect completion in the first half of 2027, 〔2〕 but that timetable now depends on a more extensive FTC review and prompt, satisfactory responses from both parties.
Bottom line: The merger remains alive, but the FTC’s deeper review makes the closing timeline less predictable and adds a meaningful regulatory hurdle to an already announced transaction.
FTC clearance or further action after Second Request compliance
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!